BACKGROUND: While numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS). OBJECTIVES AND METHODS: In this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months. RESULTS: During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis. CONCLUSION: Rituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis.
BACKGROUND: While numerous substances have been developed for the treatment of relapsing-remitting multiple sclerosis over recent years, options are still limited for patients with secondary progressive multiple sclerosis (SPMS). OBJECTIVES AND METHODS: In this observational study we present clinical and CSF findings in three patients with SPMS who were treated with rituximab for at least 15 months. RESULTS: During the observation period, no severe adverse effects occurred and the Expanded Disability Status Scale (EDSS) score stabilized in all patients after a dramatic increase over the previous years. In contrast to other publications, we showed that the time to reoccurrence of B cells was very variable and that serial CSF examinations in the course of treatment revealed a decline in intrathecal IgG synthesis. CONCLUSION:Rituximab seems to be effective in active SPMS. Restitution of the pathogenic immune response after administration of rituximab is variable. Further studies are needed to determine the optimal dosage and timing for rituximab therapy in multiple sclerosis.
Authors: Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar Journal: Arch Neurol Date: 2010-07-12
Authors: Laura Piccio; Robert T Naismith; Kathryn Trinkaus; Robyn S Klein; Becky J Parks; Jeri A Lyons; Anne H Cross Journal: Arch Neurol Date: 2010-06
Authors: Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith Journal: Ann Neurol Date: 2009-10 Impact factor: 10.422
Authors: Bibiana Bielekova; Thomas Howard; Amy N Packer; Nancy Richert; Gregg Blevins; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin Journal: Arch Neurol Date: 2009-04
Authors: Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree Journal: Arch Neurol Date: 2008-09-08
Authors: P S Rommer; T Dörner; K Freivogel; J Haas; B C Kieseier; T Kümpfel; F Paul; F Proft; H Schulze-Koops; E Schmidt; H Wiendl; U Ziemann; U K Zettl Journal: J Neuroimmune Pharmacol Date: 2015-11-20 Impact factor: 4.147
Authors: Tobias Zrzavy; Esther Daniels; Niklas Stuka; Dennis Weber; Alexander Winkelmann; Helmut Rauschka; Michael Hecker; Fahmy Aboulenein-Djamshidian; Stefanie Meister; Fritz Leutmezer; Thomas Berger; Gabriel Bsteh; Uwe Klaus Zettl; Paulus Rommer Journal: Ther Adv Chronic Dis Date: 2021-07-28 Impact factor: 5.091